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of management by reducing the number of ischemic com-
plications.
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OBJECTIVES: Despite multiple pharmacological treatment
many patients with atrial fibrillation (Afib) are not com-
pletely “arrhythmia-free,” and remain at risk of chronic
complications such as stroke and cardiac morbidity. Cur-
rently, if first line treatment fails, most patients receive sec-
ond line pharmacological treatment. The emergence of new
technologies, aiming at “curing” the arrhythmia, e.g., com-
puter guided ablation techniques, has increased interest in
the economic aspects of current second line pharmacologi-
cal treatment of Afib. Therefore, we analyzed the average 5-
year costs of second-line pharmacological management of
paroxysmal and persistent Afib in France.
METHODS: The two most relevant current treatment
strategies were included: (1) rhythm control, i.e., com-
bined therapy with class Ic and III antiarrhythmics and (2)
rate control, i.e., digoxin therapy together with a beta-
blocker or a calcium antagonist. Both strategies are often
combined with either anticoagulation therapy or aspirin.
The analysis included probabilities of stroke, sudden death
and other cardiac or non-cardiac death, and direct medical
costs of drugs, follow-up and prevention or treatment of
complications from a health care insurance perspective
(discounted at 3% per annum). Clinical data were col-
lected from prospective randomized clinical trials, medical
resource use was obtained from expert opinion (two
round pure Delphi panel) from 10 centers, and unit costs
were obtained from official sources.
RESULTS: The average total 5-year cost of pharmaco-
logical management of Afib was FF108,500 per patient
(SD  66,300; MIN  26,500; MAX  335,000). Fol-
low-up visits and hospitalizations represented the largest
proportion of costs (39%), followed by the cost of treat-
ing congestive heart failure (CHF) (33%). Patients with
prevalent CHF at start cost on average FF149,000. Pa-
tients with persistent Afib cost on average FF40,000
more than patients with paroxysmal Afib.
CONCLUSIONS: Current second line pharmaceutical
management of Afib is expensive and provides opportu-
nities for new surgical or medical interventions.
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Telmisartan (Micardis®) is a new A-II inhibitor licensed
in the UK for the treatment of people with mild to mod-
erate hypertension. Randomised controlled trials (RCTs)
suggest that the clinical outcomes of treatment with telm-
isartan may compare favorably with other products in its
class as well as with products in other classes. Therefore
the purpose of this analysis is to evaluate the extent to
which the clinical benefits are translated into economic
benefits from the perspective of the UK NHS.
Data pertaining to key clinical outcomes (efficacy and ad-
verse events) are derived from RCTs comparing telmisar-
tan with several alternative medications. The ranges are
validated by a review of the clinical literature. The costs
of hypertension treatment and the management of ad-
verse events are derived from treatment algorithms and
published sources. The clinical and cost data are com-
bined in a decision-analytic model to perform four sets of
analyses:
1. Within-trial\3-month follow-up comparisons of hy-
pertension medication costs and outcomes
2. Beyond-trial\15-month follow-up comparisons of hy-
pertension medication costs and outcomes
3. Within-trial\3-month follow-up comparisons of hy-
pertension medication costs and adverse event treat-
ment costs and outcomes
4. Beyond-trial\15-month follow-up comparisons of hy-
pertension medication costs and adverse event treat-
ment costs and outcomes
The results are reported in both cost-effectiveness and
cost-consequences format and are evaluated for their sen-
sitivity to changes in key parameter values. The policy
implications and directions for future research are dis-
cussed.
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OBJECTIVES: To evaluate hospital utilization in patients
with atrial fibrillation or flutter (AF/F) using a managed
care claims database.
METHODS: A longitudinal integrated medical and phar-
macy claims database was used to identify patients who
received an AF/F diagnosis in the emergency room and/or
hospital in calendar year 1995. The earliest date for ei-
ther primary or secondary diagnosis of AF/F was desig-
nated as the index date for the purpose of analysis. Hos-
pital utilization both before and after the index date was
obtained for four AF/F patient cohorts: patients with no
history of congestive heart failure (CHF), myocardial inf-
arction (MI) or stroke as recorded within the last 12
